ATAdam Tracy

Adam Tracy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam Tracy has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

    by Andrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, Won-Jun Kim, Bryan D Kynnap, Mihir B Doshi, Guillaume Kugener, Gabriel J Sandoval, Thomas P Howard, Ji Li, et al.

    Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful patient-derived RMC models and using whole-genome sequencing, we identified loss-of-function intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele. Biochemical and functional characterization of these models revealed that RMC requires the loss of SMARCB1 for survival. Through integration of RNAi and CRISPR-Cas9 loss-of-function genetic screens and a small-molecule screen, we found that the ubiquitin-proteasome system (UPS) was essential in RMC. Inhibition of the UPS caused a G2/M arrest due to constitutive accumulation of cyclin B1. These observations extend across cancers that harbor SMARCB1 loss, which also require expression of the E2 ubiquitin-conjugating enzyme, UBE2C. Our studies identify a synthetic lethal relationship between SMARCB1-deficient cancers and reliance on the UPS which provides the foundation for a mechanism-informed clinical trial with proteasome inhibitors.


  • Open Access

    Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

    by Andrew Lee Hong, Yuen-Yi Tseng, Jeremiah Anthony Wala, Won Jun Kim, Bryan D. Kynnap, Mihir B. Doshi, Guillaume Kugener, Gabriel J. Sandoval, Thomas P. Howard, Ji Li, et al.

    Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. Through direct-to-patient outreach, we developed genomically faithful patient-derived models of RMC. Using whole genome sequencing, we identified intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele, confirming that SMARCB1 loss occurs in RMC. Biochemical and functional characterization of these RMC models revealed that RMC depends on the loss of SMARCB1 for survival and functionally resemble other cancers that harbor loss of SMARCB1 , such as malignant rhabdoid tumors or atypical teratoid rhabdoid tumors. We performed RNAi and CRISPR-Cas9 loss of function genetic screens and a small-molecule screen and identified UBE2C as an essential gene in SMARCB1 deficient cancers. We found that the ubiquitin-proteasome pathway was essential for the survival of SMARCB1 deficient cancers in vitro and in vivo. Genetic or pharmacologic inhibition of this pathway leads to G2/M arrest due to constitutive accumulation of cyclin B1. These observations identify a synthetic lethal relationship that may serve as a therapeutic approach for patients with SMARCB1 deficient cancers.

  • TBIO-18. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE

    by Melanie Pages, Denisse Rotem, Gregory Gydush, Sarah Reed, Justin Rhoades, Gavin Ha, Chris Lo, Adam Tracy, Robert Jones, Sarah Becker, et al.

    Brain tumors often require invasive neurosurgical procedures for diagnosis and tissue acquisition to guide precision medicine. Detection of tumor-derived cell-free DNA (cfDNA) would facilitate tumor profiling without risk of surgery-related morbidity and provide a means of tumor surveillance. Our aim is to validate a sample collection procedure and develop highly sensitive and specific methodologies to detect tumor-derived cfDNA in CSF, plasma and urine from pediatric patients with brain tumors to identify clinically relevant genomic alterations. Since July 2016, we have collected blood, urine and CSF samples from 192 patients across all histological subtypes at Dana-Farber Cancer Institute/Boston Children’s Hospital. In parallel, we sequenced the tumors to identify tumor-specific genomic alterations. We optimized a method to process cfDNA and perform ultra-low pass whole genome sequencing (ULP-WGS) using unique molecular identifiers, confirming we can reliably construct sequencing libraries from CSF-, plasma- and urine-derived cfDNA. ULP-WGS has also been used to assess sequencing library quality, copy number variations (CNVs) and tumor fraction. The vast majority of samples undergoing ULP-WGS exhibited no CNVs, consistent with either absence in the tumor or low levels of tumor-derived cfDNA. To distinguish between these, we developed a hybrid capture sequencing panel covering 46 genes, allowing identification of specific mutations and fusions more common in pediatric brain tumors. We are currently assessing the specificity and sensitivity of our assays for detection of tumor-derived cfDNA. Our results will provide insights regarding the feasibility of cfDNA assays to guide clinical care in children with brain tumors.